[ET Net News Agency, 26 February 2021] Luye Pharma Group Ltd. (02186) said the clinical
trial application in relation to Nivolumab injection (LY01015) of Shandong Boan
Biotechnology Co. Ltd. (a subsidiary of the company) has been formally accepted by the
Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in
the People's Republic of China.
LY01015 is indicated for the treatment of patients with melanoma, non-small cell lung
cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma (RCC), etc. (RC)